LIA
EGRX

LS Investment Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

LS Investment Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2,255
Closed -$108K – 1509
2020
Q2 		$108K Hold
2,255
– – 0.01% 956
2020
Q1 		$104K Hold
2,255
– – 0.01% 883
2019
Q4 		$135K Buy
2,255
+265
+13% +$15.8K 0.01% 1002
2019
Q3 		$113K Hold
1,990
– – 0.01% 1030
2019
Q2 		$111K Buy
1,990
+33
+2% +$1.72K 0.01% 1048
2019
Q1 		$99K Sell
1,957
-200
-9% -$8.9K 0.01% 1096
2018
Q4 		$87K Buy
2,157
+1,067
+98% +$55K 0.01% 1108
2018
Q3 		$76K Sell
1,090
-197
-15% -$14.9K ﹤0.01% 1206
2018
Q2 		$97K Hold
1,287
– – 0.01% 1146
2018
Q1 		$68K Hold
1,287
– – ﹤0.01% 1210
2017
Q4 		$69K Buy
1,287
+218
+20% +$12.1K ﹤0.01% 1228
2017
Q3 		$64K Buy
1,069
+213
+25% +$12.9K ﹤0.01% 1274
2017
Q2 		$68K Hold
856
– – ﹤0.01% 1254
2017
Q1 		$71K Buy
856
+500
+140% +$37.2K ﹤0.01% 1233
2016
Q4 		$28K Hold
356
– – ﹤0.01% 1468
2016
Q3 		$25K Buy
+356
New +$19.7K ﹤0.01% 1455

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

LS Investment Advisors's EGRX Position: Q3 2020 in Review

LS Investment Advisors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2020, closing a stake of 2,255 shares — an estimated $108K sold.

LS Investment Advisors first reported a position in EGRX in Q3 2016 and held it in 16 quarters. The position peaked at $135K in Q4 2019. 171 funds tracked by Wall St. Rank hold EGRX as of Q3 2020.

  • LS Investment Advisors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • LS Investment Advisors sold 2,255 Eagle Pharmaceuticals, Inc. shares in Q3 2020, an estimated $108K.
  • LS Investment Advisors first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2016 and held it in 16 quarters.
  • LS Investment Advisors's Eagle Pharmaceuticals, Inc. position peaked at $135K in Q4 2019.
  • 171 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2020.

Based on LS Investment Advisors's 13F filing for Q3 2020, filed 12 Nov 2020.